May 17th 2024
Vikram M. Narayan, MD, discusses the final 5-year analysis of a phase 3 trial of nadofaragene firadenovec in patients with BCG-unresponsive NMIBC.
April 23rd 2024
Vikram Narayan, MD, discusses the mechanism of action of nadofaragene firadenovec in patients with high-risk non–muscle invasive bladder cancer.